SIRIUS Cost Data Suggests Higher Inpatient Payment Level For Eluting Stents
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness data collected by Johnson & Johnson/Cordis from trials of its Cypher sirolimus-eluting coronary stent will justify assigning the device to a new diagnosis-related group (DRG) in time for the expected 2003 U.S. launch, according to Cordis
You may also be interested in...
Cypher In-Stent Restenosis Treatment Safety Upheld By J&J Investigators
Eight-month follow-up of Johnson & Johnson/Cordis' 41-patient study evaluating the Cypher sirolimus-eluting stent for treating in-stent restenosis suggests the procedure is safe and effective, investigators reported March 19 at the American College of Cardiology annual scientific sessions in Atlanta
Cypher In-Stent Restenosis Treatment Safety Upheld By J&J Investigators
Eight-month follow-up of Johnson & Johnson/Cordis' 41-patient study evaluating the Cypher sirolimus-eluting stent for treating in-stent restenosis suggests the procedure is safe and effective, investigators reported March 19 at the American College of Cardiology annual scientific sessions in Atlanta
Drug-Coated Stents Will Pay Their Way If Priced At $2,500 Or Below – Cohen
The ability of drug-eluting stents to reduce the need for revascularization procedures justifies a price premium of up to $1,500 over regular stents, according to a cost-efficiency model by cardiologist David Cohen, MD, Beth Israel Deaconess Medical Center